Ticagrelor Inhibits Adenosine Uptake In Vitro and Enhances Adenosine-Mediated Hyperemia Responses in a Canine Model

Journal of Cardiovascular Pharmacology and Therapeutics - Tập 17 Số 2 - Trang 164-172 - 2012
J.J.J. van Giezen1, James E. Sidaway2, Philip Glaves2, Ian P. Kirk3, Jan‐Arne Björkman1
1Department of Bioscience, AstraZeneca R&D, Mölndal, Sweden
22Global Safety Assessment, AstraZeneca R&D, Alderly Park, UK
33SPDB, AstraZeneca R&D, Charnwood, UK

Tóm tắt

Aims: A routine secondary pharmacology screen indicated that reversibly binding oral P2Y12 receptor antagonist ticagrelor could inhibit adenosine uptake in human erythrocytes, suggesting that ticagrelor may potentiate adenosine-mediated responses in vivo. The aim of this study was to further characterize the adenosine uptake inhibition in vitro and study possible physiological consequences of adenosine uptake inhibition by ticagrelor in an anesthetized dog model of coronary blood flow compared to dipyridamole. Methods and Results: We measured [2-3H]adenosine uptake in purified human erythrocytes and several cell lines in the presence of ticagrelor or the known uptake inhibitor dipyridamole as a comparator. Using an open-chest dog model (beagles), we measured the left anterior descending (LAD) coronary artery blood flow during reactive hyperemia after 1 minute occlusion or intracoronary infusion of adenosine before and after administration of vehicle, ticagrelor, or dipyridamole (each n = 8). Ticagrelor concentration-dependently inhibited adenosine uptake in human erythrocytes and in cell lines of rat, canine, or human origin. In the dog model, ticagrelor and dipyridamole dose-dependently augmented reactive hyperemia after LAD occlusion, as assessed by percentage repayment of flow debt relative to control (both Ps < .05). Ticagrelor and dipyridamole also dose-dependently augmented intracoronary adenosine-induced increases in LAD blood flow relative to control (both Ps < .05). Conclusion: Ticagrelor inhibits adenosine uptake in vitro and subsequently augments cardiac blood flow in a canine model of reactive hypoxia- or adenosine-induced blood flow increases. These findings suggest that ticagrelor may have additional benefits in patients with acute coronary syndrome beyond inhibition of platelet aggregation.

Từ khóa


Tài liệu tham khảo

10.1055/s-2005-869525

10.1111/j.1538-7836.2009.03527.x

10.1111/j.1755-5922.2009.00096.x

10.1093/eurheartj/ehi754

Cannon CP, 2007, J Am Coll Cardiol, 50, 1844, 10.1016/j.jacc.2007.07.053

10.1016/j.jacc.2007.07.058

10.1056/NEJMoa0904327

10.1056/NEJMoa0706482

10.1093/eurheartj/ehp159

10.1136/hrt.2005.075077

10.1161/01.CIR.101.18.2154

10.1016/j.jacc.2005.02.061

10.1093/eurheartj/ehl094

10.1152/japplphysiol.00913.2004

AstraZeneca R&D Mölndal, data on file, study number 26709, experiment number 26709033.

AstraZeneca data on file, document SC-103269.

10.1007/s00424-003-1103-2

10.1007/s00424-003-1107-y

10.1016/j.ejphar.2004.03.026

10.1152/ajpheart.00711.2009

10.1016/j.cardiores.2003.11.031

Belardinelli L, 1998, J Pharmacol Exp Ther, 284, 1066

10.1161/01.HYP.0000144800.21037.a5

Fredholm BB, 2001, Pharmacol Rev, 53, 527

10.1111/j.1600-0773.1981.tb00916.x

10.1161/01.RES.47.6.807

10.1007/978-3-540-89615-9_6

10.1055/s-0038-1661437

AstraZeneca, data on file, study report numbers SC-103208, SC-103260, SC-103370, 0355SY, and 1805KV.

10.1161/01.CIR.82.5.1595

10.1160/TH09-12-0823

10.1016/j.jacc.2010.10.029

10.1016/S0140-6736(09)60441-4

10.1016/0002-9343(92)90784-9

10.1067/mhj.2001.116070

10.1111/j.1469-7793.1998.109br.x

Diener HC, 2008, Lancet Neurol, 7, 875, 10.1016/S1474-4422(08)70198-4

10.1056/NEJMoa0805002

10.1001/jama.1991.03460050087027

10.1161/01.CIR.81.4.1205

Perper EJ, 1991, J Nucl Med, 32, 2107

Aggrenox [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2009.

10.1056/NEJMoa0908628

10.1056/NEJMoa0908629

Thông tin
Thông tin xuất bản

Journal of Cardiovascular Pharmacology and Therapeutics

Tập 17 Số 2

164-172

Thông tin tác giả